152 related articles for article (PubMed ID: 12852754)
1. Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes.
Laufer SA; Wagner GK; Kotschenreuther DA; Albrecht W
J Med Chem; 2003 Jul; 46(15):3230-44. PubMed ID: 12852754
[TBL] [Abstract][Full Text] [Related]
2. Tetrasubstituted imidazole inhibitors of cytokine release: probing substituents in the N-1 position.
Laufer SA; Zimmermann W; Ruff KJ
J Med Chem; 2004 Dec; 47(25):6311-25. PubMed ID: 15566301
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
4. Imidazole inhibitors of cytokine release: probing substituents in the 2 position.
Laufer SA; Striegel HG; Wagner GK
J Med Chem; 2002 Oct; 45(21):4695-705. PubMed ID: 12361396
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and structure-activity relationship of aminobenzophenones. A novel class of p38 MAP kinase inhibitors with high antiinflammatory activity.
Ottosen ER; Sørensen MD; Björkling F; Skak-Nielsen T; Fjording MS; Aaes H; Binderup L
J Med Chem; 2003 Dec; 46(26):5651-62. PubMed ID: 14667219
[TBL] [Abstract][Full Text] [Related]
6. From imidazoles to pyrimidines: new inhibitors of cytokine release.
Laufer SA; Wagner GK
J Med Chem; 2002 Jun; 45(13):2733-40. PubMed ID: 12061876
[TBL] [Abstract][Full Text] [Related]
7. Identification of regioisomers in a series of N-substituted pyridin-4-yl imidazole derivatives by regiospecific synthesis, GC/MS, and 1H NMR.
Wagner GK; Kotschenreuther D; Zimmermann W; Laufer SA
J Org Chem; 2003 May; 68(11):4527-30. PubMed ID: 12762762
[TBL] [Abstract][Full Text] [Related]
8. Design and synthesis of 4-azaindoles as inhibitors of p38 MAP kinase.
Trejo A; Arzeno H; Browner M; Chanda S; Cheng S; Comer DD; Dalrymple SA; Dunten P; Lafargue J; Lovejoy B; Freire-Moar J; Lim J; Mcintosh J; Miller J; Papp E; Reuter D; Roberts R; Sanpablo F; Saunders J; Song K; Villasenor A; Warren SD; Welch M; Weller P; Whiteley PE; Zeng L; Goldstein DM
J Med Chem; 2003 Oct; 46(22):4702-13. PubMed ID: 14561090
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel imidazole-substituted dipeptide amides as potent and selective inhibitors of Candida albicans myristoylCoA:protein N-myristoyltransferase and identification of related tripeptide inhibitors with mechanism-based antifungal activity.
Devadas B; Freeman SK; Zupec ME; Lu HF; Nagarajan SR; Kishore NS; Lodge JK; Kuneman DW; McWherter CA; Vinjamoori DV; Getman DP; Gordon JI; Sikorski JA
J Med Chem; 1997 Aug; 40(16):2609-25. PubMed ID: 9258368
[TBL] [Abstract][Full Text] [Related]
10. Benzimidazolone p38 inhibitors.
Dombroski MA; Letavic MA; McClure KF; Barberia JT; Carty TJ; Cortina SR; Csiki C; Dipesa AJ; Elliott NC; Gabel CA; Jordan CK; Labasi JM; Martin WH; Peese KM; Stock IA; Svensson L; Sweeney FJ; Yu CH
Bioorg Med Chem Lett; 2004 Feb; 14(4):919-23. PubMed ID: 15012994
[TBL] [Abstract][Full Text] [Related]
11. Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.
Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Rucklin G
Bioorg Med Chem Lett; 2004 Jul; 14(13):3595-9. PubMed ID: 15177482
[TBL] [Abstract][Full Text] [Related]
12. Ones, thiones, and N-oxides: an exercise in imidazole chemistry.
Laufer S; Wagner G; Kotschenreuther D
Angew Chem Int Ed Engl; 2002 Jul; 41(13):2290-3. PubMed ID: 12203569
[No Abstract] [Full Text] [Related]
13. A novel 3D-QSAR comparative molecular field analysis (CoMFA) model of imidazole and quinazolinone functionalized p38 MAP kinase inhibitors.
Sperandio da Silva GM; Sant'Anna CM; Barreiro EJ
Bioorg Med Chem; 2004 Jun; 12(12):3159-66. PubMed ID: 15158784
[TBL] [Abstract][Full Text] [Related]
14. 5-Cyanopyrimidine derivatives as a novel class of potent, selective, and orally active inhibitors of p38alpha MAP kinase.
Liu C; Wrobleski ST; Lin J; Ahmed G; Metzger A; Wityak J; Gillooly KM; Shuster DJ; McIntyre KW; Pitt S; Shen DR; Zhang RF; Zhang H; Doweyko AM; Diller D; Henderson I; Barrish JC; Dodd JH; Schieven GL; Leftheris K
J Med Chem; 2005 Oct; 48(20):6261-70. PubMed ID: 16190753
[TBL] [Abstract][Full Text] [Related]
15. 1-substituted 4-aryl-5-pyridinylimidazoles: a new class of cytokine suppressive drugs with low 5-lipoxygenase and cyclooxygenase inhibitory potency.
Boehm JC; Smietana JM; Sorenson ME; Garigipati RS; Gallagher TF; Sheldrake PL; Bradbeer J; Badger AM; Laydon JT; Lee JC; Hillegass LM; Griswold DE; Breton JJ; Chabot-Fletcher MC; Adams JL
J Med Chem; 1996 Sep; 39(20):3929-37. PubMed ID: 8831759
[TBL] [Abstract][Full Text] [Related]
16. A single amino acid substitution makes ERK2 susceptible to pyridinyl imidazole inhibitors of p38 MAP kinase.
Fox T; Coll JT; Xie X; Ford PJ; Germann UA; Porter MD; Pazhanisamy S; Fleming MA; Galullo V; Su MS; Wilson KP
Protein Sci; 1998 Nov; 7(11):2249-55. PubMed ID: 9827991
[TBL] [Abstract][Full Text] [Related]
17. Roflumilast inhibits lipopolysaccharide-induced inflammatory mediators via suppression of nuclear factor-kappaB, p38 mitogen-activated protein kinase, and c-Jun NH2-terminal kinase activation.
Kwak HJ; Song JS; Heo JY; Yang SD; Nam JY; Cheon HG
J Pharmacol Exp Ther; 2005 Dec; 315(3):1188-95. PubMed ID: 16126838
[TBL] [Abstract][Full Text] [Related]
18. SAR of 4-hydroxypiperidine and hydroxyalkyl substituted heterocycles as novel p38 map kinase inhibitors.
Revesz L; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Zimmerlin AG
Bioorg Med Chem Lett; 2000 Jun; 10(11):1261-4. PubMed ID: 10866395
[TBL] [Abstract][Full Text] [Related]
19. Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation.
Gill AL; Frederickson M; Cleasby A; Woodhead SJ; Carr MG; Woodhead AJ; Walker MT; Congreve MS; Devine LA; Tisi D; O'Reilly M; Seavers LC; Davis DJ; Curry J; Anthony R; Padova A; Murray CW; Carr RA; Jhoti H
J Med Chem; 2005 Jan; 48(2):414-26. PubMed ID: 15658855
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of imidazole based compounds as cytochrome P-450 inhibitors.
Ahmed S; Smith JH; Nicholls PJ; Whomsley R; Cariuk P
Drug Des Discov; 1995 Aug; 13(1):27-41. PubMed ID: 8882899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]